Skip to main content Skip to main menu
UF Health University of Florida
Continuing Medical Education College of Medicine
Register for an Event

Pharmacogenetic Testing and Consultation for Patients

activity
Post test

Presented by:
Emily J. Cicali, Pharm.D., BCPS
Associate Professor, College of Pharmacy

Co-Presenters:
Madeline Norris, Pharm.D.
Post-Doctoral Fellow, Clinical Pharmacogenomics Pharmacist

Faculty Disclosure:

Drs. Cicali and Norris have disclosed that they have no relevant financial relationship(s). No one else in a position to control content has any financial relationships to disclose.

Conflict of interest information for the CME Advisory Committee members can be found on the following website: https://cme.ufl.edu/disclosure/. All relevant financial relationships have been mitigated.

Release Date: September 22, 2023
Expiration Date: September 21, 2025

Target Audience: All physicians

Learning Objectives:

As a result of participation in this activity, participants should be able to:

  1. Summarize pharmacogenetic testing & how genetic variations affect the body’s response to certain medications.
  2. Review the gene-drug pairs relevant for Psychiatry patients and relevant evidence.
  3. Discuss how these gene-drug pairs may impact the patient’s response to certain medications & dosages.
  4. Review Psychiatry patient cases.

Requirements for successful completion: Certificates are awarded upon successful completion (80% proficiency) of the post-test.

Accreditation: The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit: The University of Florida College of Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Resources for further study:

  1. Hicks JK, et al., Clin Pharmacol Ther. 2015;98(2):127-134.
  2. Bousman, Chad A et al., Clin Pharmacol and Ther. 2023; 114(1): 51-68.
  3. Solomon HV, et al., Psychiatry Res. 2019 Jan;271:604-613. PMID: 30554109.
  4. Oslin DW, et al., JAMA. 2022 Jul 12;328(2):151-161.
  5. Smith RL, et al. Br J Clin Pharmacol. 2023;89(7):2246-2253.
  6. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021411s040lbl.pdf
  7. Milosavljevic F, et al. JAMA Psychiatry. 2020; PMID: 33237321.
  8. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021436s038,021713s030,021729s022,021866s023lbl.pdf
  9. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202971s008lbl.pdf
  10. https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/RISPERDAL-pi.pdf
  11. Zhang L et al. Pharmacotherapy. 2020; PMID: 32519344.
  12. Jukic et al. Lancet Psychiatry. 2019. PMID: 31000417.
  13. Kazeem A et al. Ped Res. 2019. PMID: 30661084.
  14. Lu JY et al. Pharmacogenomics 2020 PMID: 32969762.
  15. https://precisionmedicine.ufhealth.org/phenoconversion-calculator/
  16. Jallaq SA et al. Journal of Child and Adolescent Psychopharmacology. 2020. PMID: 32845723.
  17. Lemke L et al., Frontiers. August 2023. https://www.frontiersin.org/articles/10.3389/fphar.2023.1179364/full

If you have any questions please feel free to contact Nancy Boyd at (352) 594-4298 or at nancy.boyd@ufl.edu